Shanghai, China, 10 April 2025 – MicroPort® recently announced that two of its latest innovations - the Hector™ Multi-Branch Thoracic Stent Graft System (Hector™), developed by MicroPort® Endovastec™, and the Streamliner™ Implantable Tibial Nerve Stimulator (Streamliner™), developed by MicroPort® UniFlow - have been approved for fast-track registration as innovative medical devices by China’s National Medical Products Administration (NMPA).
Hector™ is designed to enable minimally invasive treatment of complex thoracic aortic aneurysms involving all three supra-aortic branches – an area for which no fully endovascular solutions are currently commercially available. Traditional techniques, such as the chimney and fenestration methods using standard grafts, present significant limitations in such cases. Hector™ addresses this critical clinical challenge with a fully endovascular solution for three-branch reconstruction.
Building on nearly two decades of expertise in branched stent grafts, MicroPort® Endovastec™ introduced the Castor™system, followed by the Cratos™ system, which featured an enhanced delivery system. Now, as the company’s first multi-branch stent graft, Hector™ further expands endovascular aortic treatment to the entire aortic arch, addressing a significant clinical challenge.
Hector™ integrates several key innovations, including an off-the-shelf triple-branch stent graft design, which is capable of adapting to the variable anatomical structures of the aortic arch, a swift deployment system that preserves supra-aortic vessels blood flow during operation, and a flexible yet stable bridging stent with tip-capture design.
Streamliner™ is designed for the treatment of overactive bladder (OAB), a condition managed through behavioral training, pharmacological therapy, and neuromodulation techniques. Among these, tibial nerve stimulation offers a less invasive alternative with favorable patient tolerance.
Streamliner™ features a ring-point electrode structure for optimized stimulation and supports bidirectional, programmable control via a low-energy communication protocol. Compared to traditional implantable sacral nerve stimulators, implantable tibial nerve stimulators offer advantages such as simpler surgery, minimal trauma, lower costs, and fewer post-procedure complications and side effects. Once implanted, Streamliner™ requires no patient intervention, enhancing compliance and outcomes.
With fast-track designation by NMPA, both Hector™ and Streamliner™ become available in China more quickly, supporting broader access to advanced and effective medical solutions.
About MicroPort®
Founded in 1998 on the belief that every person has the right to high quality medical treatments, MicroPort® (MicroPort Scientific Corporation; HKEX: 00853) is a global medical devices company. MicroPort® provides solutions across twelve therapeutic areas, including cardiovascular, orthopedics, cardiac rhythm management, electrophysiology, endovascular, neurovascular and surgical robotics among others. For over 26 years, MicroPort® has been breaking barriers and accelerating access to life-changing solutions so that patients everywhere can continue living better and longer lives. With therapeutic solutions that are available in more than 100 countries and over 20,000 hospitals around the world, today, every 5 seconds a patient around the world benefits from a MicroPort® life-changing solution.
More information is available at: www.microport.com